Login to Your Account



Regado wrecks, derailed by allergic events in pivotal trial

By Michael Fitzhugh
Staff Writer

Monday, August 25, 2014
Shares of Regado Biosciences Inc. (NASDAQ:RGDO) fell 60.2 percent Monday, closing at $1.13, after the company permanently terminated enrollment in a phase III trial of its lead program, the anticoagulant Revolixys Kit (REG1), following a string of serious allergic events found by its data and safety monitoring board (DSMB).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription